Sponsored Budget

POM Antwerp (50%), EFRO (40%), Hermes Fund (10%)

Project Period

To date, the anicells manufacturing site is under construction and will be operational by Q4 2019 and this, in compliance with most recent European regulations for the manufacturing of advanced therapeutic medicinal products. anicells’ facilities will have 5 sterile cell-processing cleanrooms with classification B and C, including hi-tech closed-system cell-purification devices as well as a QC lab.